Skip to main content

Table 4 Association between atopy and remission of respiratory symptoms classified by the treatment group and gender

From: Atopy is a risk factor for respiratory symptoms in COPD patients: results from the EUROSCOP study

Respiratory symptom

Total population

Males

Females

 

OR (95% CI) of phadiatop

OR (95% CI) of phadiatop

OR (95% CI) of phadiatop

 

Placebo

Budesonide

Placebo

Budesonide

Placebo

Budesonide

Wheezing at any time

0.99 (0.59–1.67)

1.18 (0.70–1.99)

0.88 (0.48–1.60)

1.26 (0.70–2.26)

2.06 (0.55–7.78)

0.51 (0.15–1.71)

Cough day/night or in a.m.

0.85 (0.53–1.36)

1.93 (1.11–3.37)*,$

0.87 (0.52–1.45)

1.94 (1.05–3.57) *

0.79 (0.26–2.41)

1.84 (0.47–7.30)

Phlegm in day/night or in a.m.

1.21 (0.72–2.03)

1.67 (0.99–2.82)#

1.14 (0.65–2.00)

1.63 (0.93–2.87)#

1.48 (0.34–6.45)

1.53 (0.28–8.26)

Trouble with breathing

0.84 (0.48–1.47)

1.76 (0.99–3.11)#

0.96 (0.50–1.82)

2.76 (1.45–5.26) *,$

0.47 (0.18–1.21)

0.43 (0.17–1.12)#

Woken with chest tightness

2.18 (0.97–4.90)#

2.32 (0.60–8.91)

2.17 (0.67–6.99)

1.33 (0.22–7.85)

5.76 (1.67–19.86) *

8.82 (0.63–123.66)

Attack of dyspnea after activity

1.01 (0.52–1.95)

1.11 (0.63–1.96)

1.04 (0.49–2.20)

0.87 (0.46–1.64)

1.03 (0.29–3.63)

3.67 (0.68–19.70)

  1. *OR is significant at p < 0.05. Each model was adjusted for sex, age, BMI, pack years of smoking, number of cigarette and FEV1 % pred.
  2. #Trend (0.05 < p. value < 0.1). $Interaction between Phadiatop and treatment group has a p.value < 0.05.